Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer - Wikidata - awgldk - TriplyDB

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

http://www.wikidata.org/entity/Q34012047

about

Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases.The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.Ki-67 Expression by Immunohistochemistry and Quantitative Real-Time Polymerase Chain Reaction as Predictor of Clinical Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy.Ki67 Heterogeneity in Estrogen Receptor-Positive Breast Cancers: Which Tumor Type Has the Most Heterogeneity?Menstrual cycle could affect Ki67 expression in estrogen receptor-positive breast cancer patients.

P2860

Q35677301-86CEF33C-E7FB-4073-A075-ED22C4209EDC Q38771946-83ACB3A6-1954-4761-BBFC-28423754E6BE Q47160829-29E774BF-F1CE-4E6F-A7AB-26811230DE46 Q52680900-96BF0734-D49A-4BF8-909D-D5C5C2AA6105 Q53351065-29C45C70-51DB-48B0-BAF9-BE7960FA4CF8 Q53472937-13542EC5-540B-47F2-98F8-99EC8D2DD10C

P2860

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

http://www.wikidata.org/entity/Q34012047

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Ki67 expression and the effect ...... al HER2-negative breast cancer

@ast

Ki67 expression and the effect ...... al HER2-negative breast cancer

@en

Ki67 expression and the effect ...... al HER2-negative breast cancer

@nl

type

label

Ki67 expression and the effect ...... al HER2-negative breast cancer

@ast

Ki67 expression and the effect ...... al HER2-negative breast cancer

@en

Ki67 expression and the effect ...... al HER2-negative breast cancer

@nl

prefLabel

Ki67 expression and the effect ...... al HER2-negative breast cancer

@ast

Ki67 expression and the effect ...... al HER2-negative breast cancer

@en

Ki67 expression and the effect ...... al HER2-negative breast cancer

@nl

P1433

Q34012047-426B28B8-D55E-41A0-93F5-AE3E6D4EFBC3

P1476

Q34012047-959B42C5-C4C3-483C-B957-0DCE1419FF80

P2093

Q34012047-15C5E99C-8984-4D8D-875D-462CFCAAA343

Q34012047-3D647BF5-C6E3-492A-BB78-44D3E803CD8B

Q34012047-4D3AA9BB-C0CE-4510-9333-A4DDE872259D

Q34012047-57D1D7E5-1B42-4591-8415-B66ABF54F57A

Q34012047-61575F60-13C0-40F4-B4B0-1B8887E68248

Q34012047-83110BBB-639A-4E26-B655-42641FE42593

Q34012047-93D053B1-2BAC-4C46-8C9A-E675E5C1480E

Q34012047-A141B36D-44E5-4285-8389-49BCEB9A3A6E

Q34012047-D0D3521C-6543-472F-816A-E656A8EA5F4F

Q34012047-FFD5F66A-4CFF-4D8B-823D-2F0B4173D798

P2860

Q34012047-05CAD8E0-B442-4673-862F-43C9DE9A9126

Q34012047-08A1BEE0-1553-40E5-931A-23630F9CB9BA

Q34012047-14C7705D-C06F-4699-BCEC-B92C809F06E3

Q34012047-15E12931-7D31-4672-99A7-91A98372B3C1

Q34012047-166BB96D-0F87-4790-B168-73CC1532D44A

Q34012047-16C32A4B-8748-4DB1-A244-571624225CAB

Q34012047-1AFF5C38-AF3D-4A31-9433-C8D04F6893ED

Q34012047-2F675C0E-65FC-400C-87F9-E84CFC15DC8A

Q34012047-3D01C919-D8EE-48FC-B109-0B4D7D48CDD9

Q34012047-41C10534-E42C-49A3-8796-A007CCD26EEF

P2888

Q34012047-987E11AB-ABAD-45DE-8288-FDC394186127

P304

Q34012047-CBD49D0E-A0FE-43A7-8A94-CA9F82B50D25

P31

Q34012047-F850EA99-2CA6-4D22-85D1-65604E867653

P356

Q34012047-46143962-8BE9-4A9F-BE52-BA4FBBED01FD

P407

Q34012047-2AFC7203-9CAE-43FC-A753-3690C33507CC

P478

Q34012047-BF33DA62-AF41-418E-86E3-99D7D07DE62C

P577

Q34012047-73919C92-A061-4572-999A-B11A0672DEDE

P5875

Q34012047-87047A95-44F3-49DA-900C-7C23BD266620

P6179

Q34012047-4889A930-2B09-42FC-8BA9-5AF44C44E714

P698

Q34012047-0BEDE99E-A0F0-4C29-8E56-E37D5D945585

P921

Q34012047-F4F2A772-8FC8-474A-9788-19A83305D285

P932

Q34012047-BA185EF3-3A0B-4E0C-99CC-AC77FD7746A5

P356

1471-2407-14-550

P1433

P1476

Ki67 expression and the effect ...... al HER2-negative breast cancer

@en

P2093

Atsushi Arakawa

http://www.w3.org/2001/XMLSchema#string

Emi Tokuda

http://www.w3.org/2001/XMLSchema#string

Fumie Igari

http://www.w3.org/2001/XMLSchema#string

Hideo Shimizu

http://www.w3.org/2001/XMLSchema#string

Hiroshi Sonoue

http://www.w3.org/2001/XMLSchema#string

Koji Senuma

http://www.w3.org/2001/XMLSchema#string

Masahiko Tanabe

http://www.w3.org/2001/XMLSchema#string

Mitsue Saito

http://www.w3.org/2001/XMLSchema#string

Taijiro Kosaka

http://www.w3.org/2001/XMLSchema#string

Yoshiya Horimoto

http://www.w3.org/2001/XMLSchema#string

P2860

Repeated observation of breast tumor subtypes in independent gene expression data sets

How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests.

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.

Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study.

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome.

P2888

1471-2407-14-550

P304

550

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-14-550

http://www.w3.org/2001/XMLSchema#string

P407

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264393018

http://www.w3.org/2001/XMLSchema#string

P6179

1050263495

http://www.w3.org/2001/XMLSchema#string

P698

25073969

http://www.w3.org/2001/XMLSchema#string

P921

P932

4124146

http://www.w3.org/2001/XMLSchema#string